

**PRESS RELEASE**

27 June 2023 13:45:00 CEST



## **Lipum AB - Report from the Extraordinary General Meeting**

**An Extraordinary General Meeting (the "EGM") in Lipum AB (publ), corporate identity number 556813-5999 ("Lipum" or the "Company") today resolved to approve the Board of Directors' resolution on a rights issue of up to 2,870,334 new shares.**

On 8 June 2023, the Board of Directors resolved, subject to approval by an EGM, on a rights issue of up to 2,870,334 new shares at a subscription price of SEK 9.20 per share (the "**Rights Issue**"). The EGM today approved the Board of Directors' resolution on the Rights Issue.

The minutes from the EGM (in Swedish) will be available on Lipum's website, [www.lipum.se/bolagsstyrning/](http://www.lipum.se/bolagsstyrning/).

### **Contacts**

Einar Pontén, CEO

E-post: [einar.ponten@lipum.se](mailto:einar.ponten@lipum.se)

Mobile: +46 70 578 34 95

Web: [www.lipum.se](http://www.lipum.se)

### **About Us**

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

### **Attachments**

[Lipum AB - Report from the Extraordinary General Meeting](#)